REGENERON PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
REGENERON PHARMACEUTICALS, INC. (REGN) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $1.10 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $1.10B.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | $1.10B 10-K · filed 2026-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |